Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398280 | 0.88 | — | — | |
| SCHEMBL16398516 | 0.88 | RAB9A (0.30) | — | |
| SCHEMBL16398239 | 0.85 | CYP1A2 (0.39) | ALDH1A1MRGPRX4 | |
| SCHEMBL16397921 | 0.81 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL16398384 | 0.79 | HTR2A (0.31) | — | |
| SCHEMBL25136149 | 0.79 | HPGD (0.37) | ALDH1A1 | |
| SCHEMBL16397845 | 0.78 | GLP1R (0.31) | — | |
| SCHEMBL16398124 | 0.78 | KDM4E (0.42) | ALDH1A1 | |
| SCHEMBL17728109 | 0.78 | — | — | |
| SCHEMBL16398101 | 0.77 | GLP1R (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004079-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3004079-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-17 | — | — | EP | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-3004079-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195323-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | ALDH1A1 1476/4885MRGPRX4 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.